此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Non-invasive Glucose Measurement With Raman Technology in Patients With Type 1 and Type 2 Diabetes

2019年12月3日 更新者:RSP Systems A/S

Non-invasive Glucose Measurement With Raman Technology. Calibration of Newly Developed Devices in Patients With Type 1 and Type 2 Diabetes - Glucobrunn Study

The study was established to collect data and reference measurements in order to establish calibration models for the Prototype 0.3

研究概览

地位

完全的

详细说明

Subjects are recruited at two different sites.

Site 1: In group 1 subjects will on their regular stay in the clinic perform four measurement sessions a day. A measurement session consist of a reference capillary blood sample and two measures on the IMD.

Site 2: The study in group 2 consists of 26 home-based measurements and two in-clinic days. During the home measurements, 6 measurement sessions will be performed by the subjects a day. A measurement session consists of two reference BGMs, two reference CGMs and two measurements on the device. On in-clinic visits, subjects will be administered high glucose breakfast and the following 6-7 hours, measurement sessions are performed every 15 minutes.

研究类型

介入性

注册 (实际的)

47

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Bad Heilbrunn、德国、83670
        • m&i-Fachklinik Bad Heilbrunn - Zentrum für Diabetes und Stoffwechselerkrankungen
      • Ulm、德国、89081
        • Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • At least 18 years of age
  • Have a diagnosis of type 1 or type 2 diabetes mellitus (for RSP-09-02, only patients with type 1 diabetes)
  • Skin phototype 1-4
  • Be willing to perform a minimum of 6 / 12 (31 during excursion days) finger sticks per day during the study
  • Be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol
  • Be willing to provide written signed and dated informed consent

Exclusion Criteria:

  • Inability to comply with the study procedures as described by the study protocol, according to the opinion of the investigator, due to e.g. known psychiatric diagnoses, lack of cognitive ability, alcohol dependency, drug use, psychosocial overload
  • Have known severe allergy to medical grade adhesive or isopropyl alcohol used to clean the skin
  • Be breastfeeding, pregnant, attempting to conceive or not willing and able to practice birth control during the study execution (applicable to female subjects only)
  • Unable to hold hand/arm steadily (including tremors and Parkinson's Disease)
  • Severe diabetes related complications such as advanced autonomic neuropathy, kidney disease, foot ulcers, legal blindness, or symptomatic cardiovascular disease as evidenced by a history of cardiovascular episode(s)
  • Systemic or topical administration of glucocorticoids for the past 7 days
  • Undergoing dialysis treatment
  • Have extensive skin changes/diseases at the proposed measurement site (thenar) that could interfere with the accuracy of interstitial glucose measurements
  • Have a concomitant medical condition which could interfere with the study devices (study arm 1: intake of acetaminophen study arm 2: intake of salicylic acid or higher doses of ascorbic acid)
  • Unsuitable for participation due to any other cause as determined by the Investigator. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation e.g. with required documentation
  • Dependency from the sponsor or the clinical investigator (e.g. co-workers of the sponsor, the study site, and/ or their families)

Additional exclusion criteria for study arm 2:

  • Severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months prior to enrollment
  • Hypoglycemia unawareness

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:RSP-09-01
Enrolled subjects will perform 4 daily measurement session during their regular stay at the clinic. A measurement session consists of a reference capillary blood sample and two measurements on the Prototype 0.3.
Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
实验性的:RSP-09-02
Enrolled subjects will measure at home for 26 six days and visit the clinic two times. During home measurements, 6 measurement sessions will be performed by the subject a day. A measurement session consists of two BGMs, two CGMs and two measurements on the Prototype 0.3. On in-clinic visits the subject will be administered a high glucose breakfast and the following 6-7 hours, measurement sessions will be performed every 15 minutes.
Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Generation and validation of predictive models by Inter Subject Unified Performance (ISUP).
大体时间:2 years

Spectral Raman data will be collected together with paired reference measurements. Collected data will be used to generate calibration models capable of predicting tissue glucose levels.

Models will be validated on independent data sets using the ISUP measure.

2 years
Generation and validation of predictive models by Mean Absolute Relative Difference (MARD) measures
大体时间:2 years

Spectral Raman data will be collected together with paired reference measurements. Collected data will be used to generate calibration models capable of predicting tissue glucose levels.

Models will be validated on independent data sets using the MARD measure.

2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Guido Freckmann, Dr.、Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年11月22日

初级完成 (实际的)

2019年8月5日

研究完成 (实际的)

2019年8月5日

研究注册日期

首次提交

2018年11月21日

首先提交符合 QC 标准的

2018年12月18日

首次发布 (实际的)

2018年12月19日

研究记录更新

最后更新发布 (实际的)

2019年12月4日

上次提交的符合 QC 标准的更新

2019年12月3日

最后验证

2019年12月1日

更多信息

与本研究相关的术语

其他研究编号

  • RSP-09

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅